Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
-
Published:2024-05
Issue:5
Volume:9
Page:103009
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Meyer-Wilmes P.ORCID, Huober J., Untch M.ORCID, Blohmer J.-U., Janni W., Denkert C., Klare P., Link T., Rhiem K., Bayer C.ORCID, Reinisch M.ORCID, Bjelic-Radisic V., Zahm D.M., Hanusch C., Solbach C., Heinrich G., Hartkopf A.D., Schneeweiss A., Fasching P., Filmann N., Nekljudova V.ORCID, Holtschmidt J., Stickeler E.ORCID, Loibl S.
|
|